Thyroid hormone, immunoglobin and complements for predicting hepatocellular carcinoma development in patients with hepatitis B virus-related liver cirrhosis

Table 5 Risk factors for hepatocellular carcinoma in patients with liver cirrhosis (internal subgroup)

Baseline variables	Univariate			Multivariate
	95%CI	P value	95%CI	P value	95%CI	P value
Age (years)	1.088	1.022-1.158	< 0.01	1.08	1.002-1.163	0.04
Male	1.552	0.391-6.162	0.53
Decompensated cirrhosis	9.667	1.989-46.972	< 0.01	5.476	0.906-33.101	0.06
Diabetes	3	0.877-10.265	0.08
Alanine transaminase (U/L)	0.992	0.978-1.006	0.26
Gamma-glutamyl transpeptidase (U/L)	1.007	1.001-1.014	0.03	1.01	1.002-1.019	0.01
Total bilirubin (µmol/L)	1.003	0.969-1.038	0.87
International normalized ratio	0.248	0.008-7.998	0.43
Platelet (E+09/L)	0.985	0.971-1.000	0.04
Total triiodothyronine (nmol/L)	0.519	0.113-2.384	0.4
Total tetraiodothyronine (nmol/L)	0.994	0.973-1.015	0.55
Free triiodothyronine (pmol/L)	1.008	0.472-2.152	0.98
Free tetraiodothyronine (pmol/L)	1.102	0.807-1.505	0.54
Thyroid-stimulating hormone (μIU/mL)	1.173	0.670-2.055	0.58
IgM (g/L)	1.574	0.792-3.126	0.2
IgA (g/L)	0.986	0.638-1.522	0.95
IgG (g/L)	0.96	0.834-1.105	0.57
Complement 3 (g/L)	1.588	0.081-31.080	0.76
Complement 4 (g/L)	0.096	0-462.908	0.59

Ig: Immunoglobulin; OR: Odds ratio.